Co-Authors
This is a "connection" page, showing publications co-authored by L JEFFREY MEDEIROS and GUILIN TANG.
Connection Strength
3.351
-
Clinical impact of 5'MYC or 3'MYC gain/loss detected by FISH in patients with aggressive B-cell lymphomas. Cancer Genet. 2023 04; 272-273:1-8.
Score: 0.870
-
Isolated del(5q) in Patients Following Therapies for Various Malignancies May Not All Be Clinically Significant. Am J Clin Pathol. 2015 Jul; 144(1):78-86.
Score: 0.518
-
3'CBFB deletion in CBFB-rearranged acute myeloid leukemia retains morphological features associated with inv(16), but patients have higher risk of relapse and may require stem cell transplant. Ann Hematol. 2022 Apr; 101(4):847-854.
Score: 0.205
-
Myeloid/lymphoid neoplasms with FLT3 rearrangement. Mod Pathol. 2021 09; 34(9):1673-1685.
Score: 0.195
-
t(3;8)(q26.2;q24) Often Leads to MECOM/MYC Rearrangement and Is Commonly Associated with Therapy-Related Myeloid Neoplasms and/or Disease Progression. J Mol Diagn. 2019 03; 21(2):343-351.
Score: 0.165
-
Characteristics and clinical significance of cytogenetic abnormalities in polycythemia vera. Haematologica. 2017 09; 102(9):1511-1518.
Score: 0.147
-
Prognostic impact of acquisition of cytogenetic abnormalities during the course of chronic myelomonocytic leukemia. Am J Hematol. 2015 Oct; 90(10):882-7.
Score: 0.131
-
Isolated +15 in bone marrow: disease-associated or a benign finding? Leuk Res. 2015 Jan; 39(1):72-6.
Score: 0.124
-
MLL gene amplification in acute myeloid leukemia and myelodysplastic syndromes is associated with characteristic clinicopathological findings and TP53 gene mutation. Hum Pathol. 2015 Jan; 46(1):65-73.
Score: 0.123
-
Clinically silent clonal cytogenetic abnormalities arising in patients treated for lymphoid neoplasms. Leuk Res. 2014 Aug; 38(8):896-900.
Score: 0.120
-
Cytogenetic risk stratification of 417 patients with chronic myelomonocytic leukemia from a single institution. Am J Hematol. 2014 Aug; 89(8):813-8.
Score: 0.120
-
Homozygous inv(11)(q21q23) and MLL gene rearrangement in two patients with myeloid neoplasms. Int J Clin Exp Pathol. 2014; 7(6):3196-201.
Score: 0.120
-
Chronic lymphocytic leukemia with t(14;18)(q32;q21). Hum Pathol. 2013 Apr; 44(4):598-605.
Score: 0.107
-
Multi-color CD34? progenitor-focused flow cytometric assay in evaluation of myelodysplastic syndromes in patients with post cancer therapy cytopenia. Leuk Res. 2012 Aug; 36(8):974-81.
Score: 0.105
-
Precursor B-acute lymphoblastic leukemia occurring in patients with a history of prior malignancies: is it therapy-related? Haematologica. 2012 Jun; 97(6):919-25.
Score: 0.102
-
High-grade B-cell Lymphoma With MYC Rearrangement and Without BCL2 and BCL6 Rearrangements Is Associated With High P53 Expression and a Poor Prognosis. Am J Surg Pathol. 2016 Feb; 40(2):253-61.
Score: 0.034
-
Lymphomatous variant of hairy cell leukaemia: a distinctive presentation mimicking low-grade B-cell lymphoma. Histopathology. 2015 Nov; 67(5):740-5.
Score: 0.032
-
The clinical significance of negative flow cytometry immunophenotypic results in a morphologically scored positive bone marrow in patients following treatment for acute myeloid leukemia. Am J Hematol. 2015 Jun; 90(6):504-10.
Score: 0.032
-
Systemic mastocytosis with associated clonal hematological non-mast cell lineage disease: clinical significance and comparison of chomosomal abnormalities in SM and AHNMD components. Am J Hematol. 2013 Mar; 88(3):219-24.
Score: 0.028
-
Immunophenotypic heterogeneity of normal plasma cells: comparison with minimal residual plasma cell myeloma. J Clin Pathol. 2012 Sep; 65(9):823-9.
Score: 0.026
-
Therapy-related myeloid neoplasms following fludarabine, cyclophosphamide, and rituximab (FCR) treatment in patients with chronic lymphocytic leukemia/small lymphocytic lymphoma. Mod Pathol. 2012 Feb; 25(2):237-45.
Score: 0.025
-
Acute erythroid leukemia: a reassessment using criteria refined in the 2008 WHO classification. Blood. 2010 Mar 11; 115(10):1985-92.
Score: 0.022